Table 1.

Demographic and laboratory data, medications, and comorbidities of patients with RA at baseline (Month 0).

Categories	Items	Mean ± S.D.	Range
Demographic data
	Gender	F:M = 38:12
	Total visits	147
	Age	56.0 ± 11.5	27–73
	Disease duration (months)	119.8 ± 61.7	10–233
Laboratory and clinical data
	CRP (mg/L)	3.88 ± 4.24	0.2–16.7
	ESR (mm/hr)	13.9 ± 8.8	2–39
	RF (IU/mL)	73.8 ± 117.0	0.9–512
	Anti-CCP (CU)	463.4 ± 631.6	4.2–2776.7
	DAS28-ESR	2.08 ± 0.72	0.49–3.90
	TJC	0.5 ± 1.0	0–4
	SJC	0.2 ± 0.5	0–2
	HAQ-DI score	0.2 ± 0.5	0–2
Corticosteroids
	Prednisolone (n = 2, 4.0%)	2.5 ± 0.0 mg/day	2.5–2.5
	Methylprednisolone (n = 1, 2.0%)	4.0 mg/day	-
cDMARDs
	Sulfasalzine (n = 35, 70.0%)	2057.1 ± 627.5 mg/day	500–3000
	Methotrexate (n = 30, 60.0%)	10.7 ± 4.10 mg/week	5–20
	Hydroxychloroquine (n = 25, 50.0%)	316.0 ± 98.7 mg/day	200–400
	Leflunomide (n = 8, 16.0%)	17.5 ± 4.6 mg/day	10–20
	Azathioprine (n = 6, 12.0%)	100.0 ± 31.6 mg/day	50–150
bDMARDs
	Abatacept (n = 4, 8.0%)	395.9 ± 157.7 mg/4 weeks	166.7–500.0
	Golimumab (n = 1, 2.0%)	50 mg/4 weeks	-
	Certolizumab (n = 1, 2.0%)	400 mg/4 weeks	-
tDMARDs
	Tofacitinib (n = 1, 2.0%)	10 mg/day	-
Comorbidities
	Hypertension (n = 23, 46%)
	Type 2 diabetes mellitus (n = 1, 2%)
	Chronic kidney disease (n = 4, 8%)
	Myocardial infarction (n = 1, 2%)

These parameters were measured upon patient enrollment. CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide; DAS28-ESR: Disease Activity Score 28-ESR; TJC: tender-joint count; SJC: swollen-joint count; HAQ-DI: Health Assessment Questionnaire-Disability Index. cDMARDs: conventional disease-modifying anti-rheumatic drugs; bDMARDs: biologic disease-modifying anti-rheumatic drugs; tDMARDs: targeted disease-modifying anti-rheumatic drugs. Normal ranges: CRP < 5 mg/L, ESR < 30 mm/h for women and ESR < 20 mm/h for men, RF < 15 IU/mL, and anti-CCP ≤ 20 CU.